Eli Lilly Acquires AtaiBeckley in $2.8 Billion Deal

Eli Lilly (LLY) has agreed to acquire AtaiBeckley (ATAI) for up to $3.8 billion, including performance milestones. The deal marks LLY's entry into psychedelic medicine and is expected to diversify its pipeline beyond weight-loss and diabetes drugs.

By Wajeeh Khan Thu, July 16, 2026 at 8:10 PM GMT+3 2 min read · Yahoo Finance · July 16, 2026, 17:10 UTC

Eli Lilly Acquires AtaiBeckley in $2.8 Billion Deal

Tickers: $ATAI $LLY

Topics: clinical_trials pharmaceuticals stock_impact

Read the full article at Yahoo Finance

More World news

Jensen Huang Resigns as Nvidia CEO Amid Allegations of Chinese Espionage The Verge · November 12, 2026, 16:30 UTC
Rising New Vehicle Monthly Payments Pose Affordability Risks for Ford and General Motors Motley Fool · November 12, 2026, 16:33 UTC
SpaceX Shares Rise Following Nvidia CEO Jensen Huang Resignation Motley Fool · November 12, 2026, 16:34 UTC
tZERO Receives CFTC Approval for Derivatives Exchange and Clearing Operations PR Newswire · November 12, 2026, 16:36 UTC
enGene Therapeutics Shares Surge Following Positive Mid-Stage Trial Data and Piper Sandler Upgrade Seeking Alpha · November 12, 2026, 16:33 UTC
Former Nvidia CEO Jensen Huang to Testify Before Congress Regarding Export Controls and Security Concerns TechCrunch · November 12, 2026, 16:36 UTC
Nobu Hospitality and Infracorp Partner to Develop Luxury Destination in Bahrain PR Newswire · November 12, 2026, 16:34 UTC
Serco Group Announces $292 Million Acquisition of QinetiQ's U.S. Business Seeking Alpha · November 12, 2026, 16:30 UTC
Ag Growth International Targets $30M in Cost Savings Amid Divergent Business Performance Seeking Alpha · November 12, 2026, 16:30 UTC
Qualstar Reports Q3 Non-GAAP EPS of $0.09 and Revenue of $2.04 Million Seeking Alpha · November 12, 2026, 16:31 UTC